Prescribing in liver disease

Pirmohamed, Munir ORCID: 0000-0002-7534-7266 (2023) Prescribing in liver disease. Medicine, 51 (5). pp. 326-330.

	Text prescribing in liver disease accepted version.docx - Author Accepted Manuscript Download (106kB)
	Text Documents51-5Pirmohamed Figure 1.pptx - Author Accepted Manuscript Download (420kB)

Abstract

Patients with liver disease often require drug therapy. As the liver is the main site of drug detoxification and elimination, each person's need for therapy must be carefully assessed; the choice of the drug, its dose and the duration of therapy must be carefully considered to avoid adverse effects. Ideally, the chosen drug should have a high therapeutic index, be largely devoid of pharmacokinetic and pharmacodynamic interactions and hepatotoxic effects, and be renally eliminated. However, the ideal drug with these properties is often not available, so the dose and drug should be individualized to the patient, who should then be carefully monitored, with the duration of treatment kept as short as possible. The British National Formulary contains useful information on drugs that should be avoided or have their dosage modified in patients with liver disease.

Item Type:	Article
Uncontrolled Keywords:	Substance Misuse, Rare Diseases, Patient Safety, Chronic Liver Disease and Cirrhosis, Liver Disease, Orphan Drug, Digestive Diseases, 5.1 Pharmaceuticals, 5 Development of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6 Evaluation of treatments and therapeutic interventions, Oral and gastrointestinal, 3 Good Health and Well Being
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	22 May 2023 07:45
Last Modified:	02 Apr 2024 09:25
DOI:	10.1016/j.mpmed.2023.02.012
Related URLs:	Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3170552